Presentation Of The Congress Of The European Academy Of Allergy And Clinical Immunology (EAACI) To Be Held In Valencia From May 31 To June 3


(MENAFN- GlobeNewsWire - Nasdaq)

VALENCIA, Spain, May 30, 2024 (GLOBE NEWSWIRE) -- Under the theme "Revolutionizing Patient Care through the Power of Data Science," the congress will highlight the crucial role of Allergy and Clinical Immunology in advancing personalised care, data science, and a holistic approach to health.

Kindly be invited to the press conference presenting the Congress of the European Academy of Allergy and Clinical Immunology (EAACI), which will bring together the world's leading allergy and clinical immunology specialists in Valencia from May 31 to June 3.

The press conference will occur on Friday, May 31, at 11:00 am in the Almeria Hall, Pavilion 2, Feria Valencia (Av. de les Fires, s/n). The press conference will be conducted in English.

The following experts will be speaking:

  • Stefano Del Giacco, President of EAACI
  • Mohamed Shamji, Vice President of the EAACI Congress
  • Maria José Torres, General Secretary of EAACI
  • André Moreira, Co-President of the Scientific Program of the Congress
  • Mübeccel Akdis, Co-President of the Scientific Program of the Congress

Over the four days of the congress, the latest advances and innovations in the field of allergy and clinical immunology will be explored: new directions in immunotherapy and vaccinology, the state of drug allergies, environmental threats, big data and artificial intelligence in allergy, precision medicine, food allergies, asthma, and pediatric allergies.

If you are interested in attending the press conference, interviewing any of the spokespersons or speakers, or if you need more information, please contact us:

Also, you have the option to connect online:

Pablo Frieyro – Tel: +34 686 757 391 – ...
Silvia Martínez – Tel: +34 673 371 517 - ...
Nuria Monsó – Tel: +34 627 786 999 – ...

A photo accompanying this announcement is available at


MENAFN30052024004107003653ID1108276631


GlobeNewsWire - Nasdaq

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.